Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Durvalumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Squamous cell cancer; Urogenital cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ARCADIA
- 17 Oct 2019 Status changed from not yet recruiting to recruiting.
- 26 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 Apr 2019.
- 16 Mar 2018 New trial record